Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 100, Issue 4, Pages 329-330Publisher
WILEY
DOI: 10.1002/jso.21338
Keywords
immunotherapy; trifunctional antibody; intraperitoneal treatment; peritoneal carcinomatosis
Ask authors/readers for more resources
Prognosis of peritoneal carcinomatosis (PC) from GI tract cancers remains poor. As 30% of patients develop PC after curative surgery, prevention of PC during cancer resection would be desirable. Regarding physiopathology of PC and intraperitoneal immunology, intraoperative application of trifunctional antibodies offers advanced opportunities for destruction of intraperitoneal tumor cells and prevention of PC. First results indicated, the intraoperative treatment with trifunctional antibodies was safe and clinically feasible. Long-term results will be available in 2010. J. Surg. Oncol. 2009;100:329-330. (C) 2009 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available